Elevated homocysteine levels in human immunodeficiency virus-infected patients under antiretroviral therapy: A meta-analysis

Table 2 Characteristics of studies included in the outcome 2

Ref.	Country	Sample size(Control/HIV)	Studydesign	Hcy (µmol/L)		HHcy	ART
				ART	Non-ART
Mercié et al[42]	France	78/304	COS	12.5 ± 4.8	11.5 ± 4.3	-	-
de Larrañaga et al[34]	Argentina	31/128	CS	9.7 ± 7.1	8.0 ± 6.1	-	-
Remacha et al[23]	Spain	128/235	CS	17.3 ± 13	8.2 ± 7.8	-	Patients under ART (taking > 3 antiretroviral drugs)
Martí-Carvajal et al[41]	Venezuela	14/40	CS	10 ± 7.5	9.2 ± 6.7	48.6% non-ART; 45.5% ART	-
Currier et al[42]	United	40/41	COS	9.6 ± 5	8.0 ± 6.1	-	Patients on ART including a PI continuously for 2 yr
	States
Raiszadeh et al[35]	United	127/249	COS	7.5 ± 2.8	7.3 ± 2.4	-	-
	States
Coria-Ramirez et al[43]	Mexico	69/69	CC	24.8 ± 14.6	7.9 ± 3.4	7.3% non-ART; 79.9% ART	Patients who began ART and maintained the treatment for 6 mo

CC: Case-control; CS: Cross-sectional; COS: Cohort study; Hcy: Homocysteine; HHcy: Hyperhomocysteinenemia; PI: Protease inhibitors; ART: Antiretroviral therapy.